Every Form 4 that Elanco Animal Health (ELAN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELAN filings page.
Elanco Animal Health Inc (ELAN) reported that Executive Vice President U.S. Pet Health and Global Digital Transformation Rajeev A. Modi acquired 61.6158 Deferred Stock Units on 2026-08-21 as a grant or award. Each unit corresponds to one share of common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Modi holds a total of 9,770.3122 Deferred Stock Units directly.
Elanco Animal Health Inc (ELAN) reported that EVP and CFO Robert M. VanHimbergen acquired 8.2194 Deferred Stock Units on 2026-08-21 as a grant/award. Each unit corresponds to one share of common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year. Following this award, he directly holds 141.8242 Deferred Stock Units.
Elanco Animal Health Inc (symbol: ELAN) is the issuer of record for a Form 4 filing submitted to the SEC.
Elanco Animal Health Inc (ELAN) director Lawrence Erik Kurzius reported an open-market purchase of 40,000 shares of common stock on August 20, 2026 at a weighted average price of $23.398 per share, with individual trades ranging from $23.385 to $23.40. Following these purchases, his reported direct holdings increased to 188,647 shares of Elanco common stock.
Elanco Animal Health Inc (ELAN) reported that officer Shiv O'Neill, General Counsel and Corporate Secretary, purchased 3,998 shares of common stock on 2026-08-18 at $23.58 per share in an open-market or private transaction. After this trade, O'Neill directly holds 87,832 shares of Elanco common stock. The transaction was not made pursuant to a Rule 10b5-1 trading plan.
Elanco Animal Health Inc director Michael J. Harrington purchased 5,000 shares of common stock on 2026-08-12 in an open market or private transaction at a price of $21.82 per share. Following this transaction, his directly held position increased to 131,451 shares of Elanco common stock.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 127.7997 Deferred Stock Units on 2026-08-07 at a reference value of $22.12 per unit. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Simmons holds 25,012.1875 Deferred Stock Units directly.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported two transactions on August 7, 2026. He received a grant of 8.9069 Deferred Stock Units, each representing the right to one share of common stock or cash, bringing his Deferred Stock Unit balance to 133.6048. On the same date, he purchased 4,200 shares of common stock in multiple transactions at a weighted average price of $23.0776 per share, with individual prices ranging from $23.01 to $23.09. Following these purchases, he directly owns 137,516 shares of Elanco Animal Health common stock.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that Executive Vice President U.S. Pet Health and Global Digital Transformation Rajeev A. Modi received a grant of 66.7690 Deferred Stock Units tied to Company common stock at a reference price of $22.1200 per unit. Each unit represents the right to receive one share of common stock or the cash equivalent, settling in cash or shares after termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Modi holds a total of 9708.6964 Deferred Stock Units directly.
Elanco Animal Health Inc director Paul Herendeen reported an open-market purchase of 10,000 shares of Common Stock on August 7, 2026 at $23.685 per share. Following this transaction, his reported direct ownership increased to 111,687 common shares of Elanco Animal Health Inc.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 113.4857 deferred stock units on 2026-07-24 at $24.9100 per unit, increasing his direct deferred stock unit holdings to 24,884.3878 units. Each unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that Executive Vice President U.S. Pet Health and Global Digital Transformation Rajeev A. Modi received a grant of 59.2906 deferred stock units on 2026-07-24 at a reference value of $24.91 per unit. Each unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares after termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this grant, Modi holds 9,641.9274 deferred stock units directly.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that EVP and CFO Robert M. VanHimbergen received a grant of 7.9093 deferred stock units on July 24, 2026 at $24.91 per unit. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. After this compensation-related grant, he holds 124.6979 deferred stock units directly.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc’s president, CEO and director Jeffrey N. Simmons received a grant of 113.8973 deferred stock units on July 10, 2026, referenced at $24.8200 per unit. Following this award, he holds 24,770.9021 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares after termination of employment, or in a specified future year, under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health’s EVP and CFO, Robert M. VanHimbergen, received a grant of 7.9380 deferred stock units on 2026-07-10 at a reference value of $24.8200 per unit. Each unit represents the right to receive one share of common stock or the cash equivalent under the Executive Deferral and Stock Match Plan and will settle after employment ends or in a specified future year. Following this award, he holds 116.7886 deferred stock units directly.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc company officer Rajeev A. Modi received a grant of 59.5056 deferred stock units on July 10, 2026 at a reference price of $24.82 per unit. Each unit represents the right to one share of common stock or the cash equivalent and will settle after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Modi directly holds 9,582.6368 deferred stock units.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported a tax-related share disposition. On this Form 4, 15,336 shares of Common Stock were used at $24.64 per share to satisfy tax obligations by delivering shares to the issuer. After this tax-withholding disposition, he directly holds 133,316 shares of Elanco common stock, indicating the event is compensation- and tax-driven rather than an open-market trade.
Elanco Animal Health executive David S. Kinard received a grant of employee stock options, giving him rights to buy 25,620 shares of common stock at an exercise price of $24.09 per share. These options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, and expire on July 1, 2036. Following this grant, Kinard holds 25,620 stock options directly.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director K. Anand reported receiving 584.1121 Deferred Stock Units on June 30, 2026. These units were issued at an implied price of $24.61 per unit by deferring her director cash retainer into the company’s Directors’ Deferral Plan.
Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock and will be settled in stock when she leaves the Board. Following this compensation-related award, Anand holds a total of 10,079.5639 Deferred Stock Units directly.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health reported that executive Rajeev A. Modi received a grant of 60.1111 deferred stock units on June 26, 2026, each tied to Company common stock at a reference price of $24.57 per unit. After this award, he holds 9,523.1312 deferred stock units in total.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc reported that President and CEO Jeffrey N. Simmons received a grant of deferred stock units under a compensation plan. The award covers 115.0562 deferred stock units, each linked to one share of Elanco common stock or its cash equivalent at a reference value of $24.57 per unit.
Following this award, Simmons holds a total of 24,657.0048 deferred stock units directly. These units are designed to settle in cash or company shares after his employment ends or in a specified future year, in line with the Executive Deferral and Stock Match Plan, making this a routine, non-market, compensation-related acquisition rather than an open-market purchase.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.0187 deferred stock units tied to Elanco common stock at a reference price of $24.57 per unit. Following this award, he holds 108.8506 deferred stock units, which will settle in cash or shares after employment ends or in a specified future year.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.1514 deferred stock units of Elanco common stock at a reference price of $24.17 per unit. Following this grant, he holds 100.8319 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported a routine compensation-related transaction involving deferred stock units. He received an award of 116.9603 deferred stock units, each tied to the value of one share of Elanco common stock at a reference price of $24.17 per unit.
After this grant, his reported balance of deferred stock units increased to 24,541.9486 units. According to the plan terms, these units will settle in either cash or Elanco common shares after his employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that executive Rajeev A. Modi received a grant of 61.1059 deferred stock units tied to Elanco common stock. Each unit reflects a value of $24.17 per underlying share in the filing.
Following this award, Modi holds a total of 9,463.0201 deferred stock units directly. According to the plan terms, these units will settle in either cash or Elanco common shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported a routine compensation-related award of deferred stock units. He received 8.2608 deferred stock units, each tied to one share of common stock at a reference price of $23.85, bringing his total deferred stock units to 92.6805. These units will be settled in cash or Elanco common stock after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that officer Rajeev A. Modi received a grant of deferred stock units under a company plan. The award covers 61.9258 deferred stock units tied to Elanco common stock at a reference price of $23.85 per unit.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, according to the company’s Executive Deferral and Stock Match Plan. After this grant, Modi holds a total of 9,401.9142 deferred stock units directly.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health President and CEO Jeffrey N. Simmons received a grant of 118.5296 Deferred Stock Units tied to Company common stock. Each unit represents the right to receive one share or cash, settling after employment ends or in a future year under the Executive Deferral and Stock Match Plan, bringing his reported Deferred Stock Unit holdings to 24,424.9883 units.
Scots-Knight Denise reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Denise Scots-Knight received equity compensation awards rather than buying shares on the market. She was granted 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award to non-employee board members.
Following these grants, her directly held common stock and stock-based awards reported in the filing total 105,588 shares for one award category and 93,392 shares for the other. These awards were granted at no cash cost per unit, reflecting standard board compensation in stock-based form.
Kurzius Lawrence Erik reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director Lawrence Erik Kurzius reported two equity awards of common stock on May 21, 2026. He received 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity grant for non-employee directors.
Both awards were recorded at $0.00 per share, reflecting compensation grants rather than open-market purchases.
McDonald Kirk P reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Kirk P. McDonald received equity compensation rather than buying shares on the market. He was granted 12,196 deferred stock units as a pro-rated annual award and 4,678 restricted stock units as an annual equity award for non-employee directors. Following these grants, the filing shows direct holdings of 105,588 and 93,392 common shares tied to the respective awards.
Elanco Animal Health director Paul Herendeen reported two equity awards in the form of common stock-based units. On May 21, 2026, he acquired 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee Board members. These are compensation-related grants at no cash cost to him, not open-market purchases or sales, and increase his equity-based stake in Elanco.
Elanco Animal Health director Deborah Turner Kochevar received an equity award of 4,678 shares of common stock on May 21, 2026. The Form 4 labels this as a grant or award acquisition at no cost per share, reported as a grant of deferred stock units for non-employee Board members. Following the award, she directly owns 94,392 shares of Elanco common stock. This is a routine director compensation grant rather than an open-market purchase.
HOOVER R DAVID reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director R. David Hoover received a grant of 4,678 shares of Common Stock as deferred stock units, described as a pro-rated annual equity award for non-employee board members. The award carried a grant price of $0.00 per share, reflecting its compensation nature rather than a market purchase.
After this grant, Hoover directly holds 111,451 shares of Elanco common stock. He also has indirect holdings reported through the Suzanne A. Hoover Revocable Trust with 15,920 shares and another Revocable Trust with 150,000 shares, providing additional indirect exposure to Elanco shares.
Harrington Michael J reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Michael J. Harrington reported equity awards of common stock on May 21, 2026. He received 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee board members, both at no cash cost.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Anand K. Kapila received equity compensation, not making any open-market trades. On May 21, 2026, he was granted 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee directors. Both awards were recorded at $0.00 per share, reflecting stock-based compensation rather than a purchase. After these grants, the filing reports his direct ownership of Elanco common stock at 111,847 shares.
Ma Stacey reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director Stacey Ma received equity awards in the form of company stock. On May 21, 2026, she was granted 12,196 shares of common stock as deferred stock units and 4,678 shares as restricted stock units, both described as annual equity awards for non-employee directors. These are compensation-related grants at no cash purchase price, not open-market stock purchases or sales.
Elanco Animal Health director Art A. Garcia reported receiving stock-based compensation in the form of common stock units. On May 21, 2026, he acquired 12,196 deferred stock units as a pro-rated annual equity award for non-employee directors and 4,678 restricted stock units as an annual equity award. Both awards were granted at a stated price of $0.00 per share, reflecting compensation rather than open-market purchases. Each line in the filing shows updated direct holdings of Elanco common stock of 108,152 shares and 95,956 shares, respectively, following these grants.
Elanco Animal Health officer Rajeev A. Modi bought 4,911 shares of common stock in an open-market purchase at $20.35 per share, bringing his direct holdings to 160,812 shares. He also received a grant of 74.3671 deferred stock units, each tied to one share or its cash equivalent, which settle after employment ends or in a specified future year.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported an open-market purchase and a compensation-related award. A revocable trust associated with him bought 4,971 shares of common stock at $20.085 per share, bringing its indirect holdings to 171,971 shares. Separately, he received 142.3429 deferred stock units, each representing the right to one share of common stock or the cash equivalent, to be settled after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan. Following these updates, he directly holds 2,051,898 common shares and 24,306.4587 deferred stock units.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 9.9204 deferred stock units tied to company common stock. The award is a compensation-related acquisition at a reference price of $19.86 per unit, bringing his total deferred stock units to 84.4197. Each unit represents the right to receive one share of common stock or the cash equivalent, settling in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc officer Rajeev A. Modi reported an award of 65.6122 deferred stock units on May 1, 2026, tied to Company common stock at a reference price of $22.51 per unit. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan. Following this grant, Modi directly holds a total of 9,265.6213 deferred stock units.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health President and CEO Jeffrey N. Simmons received a grant of 125.5855 deferred stock units on May 1, 2026. These units are tied to the company’s common stock at a reference price of $22.51 per unit and are part of his compensation, not an open-market trade. Following this award, his reported deferred stock unit balance is 24,164.1158 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.7526 deferred stock units, each tied to one share of common stock at a reference value of $22.51. After this compensation award, he holds 74.4993 deferred stock units in total.
The deferred stock units represent the right to receive either cash or Elanco common stock in the future. They generally settle after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan, rather than being an open-market stock purchase or sale.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 119.3805 deferred stock units on April 17, 2026 at a reference price of $23.68 per unit. Following this award, he holds 24,038.5303 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after Simmons’ employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a small compensation-related award of deferred stock units. On this Form 4, he acquired 8.3201 deferred stock units tied to Elanco common stock, bringing his directly held deferred stock unit balance to 65.7467.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health officer Rajeev A. Modi received a grant of 62.3704 Deferred Stock Units. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent at a later time.
The units will settle in cash or shares following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan. After this award, Modi holds a total of 9,200.0091 Deferred Stock Units directly.
Elanco Animal Health Inc executive Rajeev A. Modi received a grant of deferred stock units as part of his compensation. On this award date, he acquired 64.7209 deferred stock units tied to Company common stock at a reference value of $22.82 per unit.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the Company’s Executive Deferral and Stock Match Plan. Following this grant, Modi holds a total of 9,137.6387 deferred stock units directly.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc President and CEO Jeffrey N. Simmons received a grant of 123.8795 deferred stock units on Company common stock. These units were valued at $22.82 per unit on the grant date and increase his directly held deferred stock unit balance to 23,919.1498 units.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. The units will settle in cash or shares following Simmons’ termination of employment or in a specified future year under the Company’s Executive Deferral and Stock Match Plan, making this a routine, compensation-related award rather than an open-market purchase.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.6337 deferred stock units on Company common stock, valued at $22.82 per unit. After this award, he holds a total of 57.4266 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.